-
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study
Tuesday, May 12, 2020 - 4:01pm | 621Read More...Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge. Two NASH biotechs offered contrasting updates on their drugs Monday. Independent Panel Says...
-
NGM Biopharma Shares Spike Higher On Positive NASH Study Results
Monday, February 24, 2020 - 11:45am | 425Read More...NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout. What Happened California-based NGM, which IPOed last March, announced positive preliminary top-line results from Cohort 4 of an adaptive Phase 2 study that...
-
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
Wednesday, February 5, 2020 - 5:11pm | 1290Read More...Non-alcoholic steatohepatitis, or NASH, is a metabolic disorder caused by a buildup of fat in the liver, leading to liver inflammation and damage. It belongs to a group of conditions called non-alcoholic fatty liver disease, or NAFLD. The Cause And Effect Of NASH Unlike other fatty liver diseases...
-
ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
Monday, June 17, 2019 - 1:50pm | 321Read More...ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following news of an erroneous SEC filing, said Monday ahead of the market open that findings...
-
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
Thursday, June 6, 2019 - 11:44am | 485Read More...Shares of the nano-cap, thinly traded biotech ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) were trading nearly 150-percent higher Thursday. What Happened ContraVir, which focuses on therapies for liver diseases arising from non-alcoholic steatohepatitis, or NASH, as well as chronic viral...
-
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Thursday, April 25, 2019 - 10:13am | 520Read More...Gilead Sciences, Inc. (NASDAQ: GILD), which was once considered one of the front-runners in the race to develop a drug for non-alcoholic steatohepatitis, or NASH, has been facing setback after setback. What Happened A little more than two months after it reported failed results for a late-stage...
-
Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
Friday, March 22, 2019 - 10:49am | 572Read More...Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened Conatus, which is developing emricasan along with Novartis AG (NYSE: NVS) for treating...
-
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Tuesday, February 19, 2019 - 11:36am | 649Read More...Intercept Pharmaceuticals Inc (NASDAQ: ICPT) — which is a frontrunner along with Gilead Sciences, Inc. (NASDAQ: GILD) in the non-alcoholic steatohepatitis drug development race — reported positive top-line results Tuesday for a late-stage study of its pipeline asset Ocaliva,...
-
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Wednesday, February 13, 2019 - 5:22pm | 466Read More...With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the spotlight. A clinical readout from the trial is expected this quarter. The...
-
Lipocine's NASH Candidate Shows Promise In Liver Fat Study
Thursday, January 17, 2019 - 11:00am | 421Read More...Lipocine Inc (NASDAQ: LPCN) shares were skyrocketing Thursday following the release of results from a study evaluating LPCN 1144, its pipeline asset for non-alcoholic steatohepatitis, or NASH. What Happened Lipocine announced Thursday that eight-week top-line, interim results from an ongoing...
-
Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock
Thursday, June 28, 2018 - 2:42pm | 455Read More...The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...
-
Will Intercept Stock Potential Be Blindsided By FDA Letter?
Friday, September 22, 2017 - 10:11am | 355Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...
-
Here's Why Shares Of Intercept Jumped Nearly 10% On Friday
Friday, February 10, 2017 - 10:47am | 355Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) jumped nearly 10 percent early Friday morning after the company provided an update on an ongoing clinical trial. Intercept is a biopharmaceutical company that focuses on developing and commercializing therapeutics to treat progressive non-viral...
-
A Primer On NASH
Thursday, December 15, 2016 - 10:47am | 357Read More...Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in a person's liver. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, there are no approved medicines to treat NAFLD and NASH. In a...
-
Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
Wednesday, September 21, 2016 - 10:30am | 352Read More...Allergan plc Ordinary Shares (NYSE: AGN)'s acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA) has some analysts wondering: if Allergan is willing to pay a massive 500 percent premium for Tobira, then what could possibly come next? Barrons cited Kevin Kedra, an analyst at Gabelli, who...
